Early detection of cancer can dramatically improve outcomes. Since the 1950s, there has been a 70% decrease in cervical cancer incidence and deaths because of early detection through the Pap test. Colon cancer found early has a 91% five-year survival rate, but only an 11% five-year survival rate if it spreads. SpotTumor℠ is a highly sensitive test that can catch and diagnose any cancer before it develops symptoms.
Using currently available technologies, a cancer diagnosis is not made in a significant proportion (~10%) of patients who are suspected to have cancer. One of the major reasons is that biopsy samples or Pap test samples may not contain sufficient cancer cells to allow pathologists to make an accurate diagnosis.
SpotTumor℠ is able to diagnose cancer in about 10% of the cases that are missed by conventional pathology of the samples without tumor cell amplification.
In the US, around 15 million colonoscopies and over 50 million pap smears are performed each year. We screen these samples and any other tissue to detect cancer early. SpotTumor℠ is highly sensitive and can detect cancer in a sample with as little as 10 cancer cells.
SpotTumor℠ is used during remission to monitor for cancer recurrence. Recurrences happen when a few cancer cells remain and grow after treatment. A patient may not experience symptoms after treatment, but should work with their physician to monitor for recurrence.
Another advantage of our platform is that the amplified cancers allow, without new sampling, subsequent tests such as BEATtumorTM for drug sensitivity and CAMidTM for genetic testing to suggest the best treatment options. This test is particularly useful, for example, for lung cancer, colon cancer, where biopsies are often obtained for diagnostic purposes, and for gynecological cancers for which PAP material can be obtained non-invasively.
An immediate application of our tumor cell amplification technology is early diagnosis of cancer and early detection of cancer recurrence. Cancer patients diagnosed at early stages have much better treatment outcomes and survive much longer. It is also known that early detection of recurrent cancer can improve patient outcome. Less well known is the importance of post-therapeutic assessment of residual cancer for patient survival. All three tasks become extremely difficult when the tumor is very small. JPM’s tumor cell amplification technology is useful to solving all three problems. JPM’s technology has made diagnosis for lung cancer, colon cancer and gynecological cancers that traditional pathology failed to make a cancer diagnosis or missed recurrent cancer detection.
SpotTumor℠ is highly sensitive and only requires the presence of as few as 10 cancer cells in the sample. This high sensitivity allows us to diagnose cancer missed by traditional pathology. If we identify cancer in a sample such as a biopsy from an endoscopy or colonoscopy, we further analyze it to form a diagnosis. The diagnosis will tell us where the cancer originated, which can be crucial to identifying the right treatment.
Although Pap smears are used to detect cervical cancer, Pap smear fluid can contain cancer cells from the ovaries and uterus/endometrium. SpotTumor℠ can pick up any of these cancers. If we detect cancer from a Pap smear sample, we will further analyze the cancer cells to form a diagnosis.
Minimum residual disease is the term used for the cancer cells that remain in a person after treatment when cancer is successfully in remission. These cancer cells can grow back into cancer and can be more resistant than before.
Minimum residual disease is most common in leukemias, although some solid tumors from the breast or brain will have circulating tumor cells in the lymph nodes and blood.
Our lab is CLIA Registered. We are preparing to go commercial with SpotTumor℠ as soon as we obtain our CLIA Certification this summer. In the meantime, SpotTumor℠ is for research use only. If you would like more information or are interested in ordering, please fill out the contact form and we will reach out to you.
Rapidly produces a perpetual supply primary cancer cells from a variety of patient tumor specimens.
Store your original tumor or amplified tumor cells in an account that never runs out of living tumor cells.